Data Show Durable Efficacy With Repotrectinib for Locally Advanced or Metastatic ROS1-Positive NSCLC
August 18th 2023Based on results from a trial of repotrectinib in patients with ROS1-positive locally advanced or metastatic non-small cell lung cancer, the FDA accepted the New Drug Application and set a Prescription Drug User Fee Act goal date of November 27, 2023.
Read More
Use of First-Line Treatment for Insomnia Low Among Adults With Mental Health Conditions
August 18th 2023Although the rate of people with probable insomnia who discussed their sleep habits with a physician was relatively high, the number of people who went on to seek actual treatment was low.
Read More
FDA Approves Hepzato Kit for Liver-Directed Treatment of Metastatic Uveal Melanoma
August 16th 2023Melphalan/hepatic delivery system (Hepzato Kit; Delcath Systems Inc) is currently the only liver-directed therapy approved by the FDA for the treatment of netastatic uveal melanoma and percutaneous hepatic perfusion.
Read More